# Ferumoxytol-enhanced Magnetic Resonance Imaging

Study · id `cardio:ct-nct02954510` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02954510](<https://clinicaltrials.gov/study/NCT02954510>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02954510

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 185 participants.

## Technical summary

Registry record NCT02954510. Allocation not applicable; no masking; primary purpose diagnostic. Start 2017-02-01 (actual); primary completion 2023-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 3
- Enrolled: 185 participants (planned count; ClinicalTrials.gov record NCT02954510, source copy `cardio:ctgov-nct02954510-2023-01-04`, retrieved 2026-10-26)
- Started: 2017-02-01 (actual) (ClinicalTrials.gov record NCT02954510, source copy `cardio:ctgov-nct02954510-2023-01-04`, retrieved 2026-10-26)
- Primary completion: 2023-11-01 (anticipated) (ClinicalTrials.gov record NCT02954510, source copy `cardio:ctgov-nct02954510-2023-01-04`, retrieved 2026-10-26)
- Completion: 2024-02-27 (anticipated) (ClinicalTrials.gov record NCT02954510, source copy `cardio:ctgov-nct02954510-2023-01-04`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02954510, source copy `cardio:ctgov-nct02954510-2023-01-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02954510-2023-01-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ferumoxytol-enhanced Magnetic Resonance Imaging
- Condition: Coronary Artery Disease
- Intervention (Drug): ferumoxytol
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)

## Provenance

Content hash: fcc270840359e13d3afb4467812701113e04a1735ad4b976bf5b70329f5d646e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
